Remission induction comparing infliximab and high-dose intravenous steroid, followed by treat-to-target: a double-blind, randomised, controlled trial in new-onset, treatment-naive, rheumatoid arthritis (the IDEA study)

Low-Dose Prednisone Inclusion in a Methotrexate-Based, Tight Control Strategy for Early Rheumatoid Arthritis

(2013) Marije F. Bakker   ANNALS OF INTERNAL MEDICINE

Adalimumab added to a treat-to-target strategy with methotrexate and intra-articular triamcinolone in early rheumatoid arthritis increased remission rates, function and quality of life. The OPERA Study: an investigator-initiated, randomised, double-blind, parallel-group, placebo-controlled trial

(2013) Kim Hørslev-Petersen et al.   ANNALS OF THE RHEUMATIC DISEASES

Association Between the Initiation of Anti–Tumor Necrosis Factor Therapy and the Risk of Herpes Zoster

(2013) Kevin L. Winthrop et al.   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

Infliximab for 6 months added on combination therapy in early rheumatoid arthritis: 2-year results from an investigator-initiated, randomised, double-blind, placebo-controlled study (the NEO-RACo Study)

(2012) Marjatta Leirisalo-Repo et al.   ANNALS OF THE RHEUMATIC DISEASES

Induction therapy with a combination of DMARDs is better than methotrexate monotherapy: first results of the tREACH trial

(2012) P H de Jong et al.   ANNALS OF THE RHEUMATIC DISEASES

Can flare be predicted in DMARD treated RA patients in remission, and is it important? A cohort study

(2012) Benazir Saleem et al.   ANNALS OF THE RHEUMATIC DISEASES

Clinical, functional and radiographic consequences of achieving stable low disease activity and remission with adalimumab plus methotrexate or methotrexate alone in early rheumatoid arthritis: 26-week results from the randomised, controlled OPTIMA study

(2012) Arthur Kavanaugh et al.   ANNALS OF THE RHEUMATIC DISEASES

In early rheumatoid arthritis, patients with a good initial response to methotrexate have excellent 2-year clinical outcomes, but radiological progression is not fully prevented: data from the methotrexate responders population in the SWEFOT trial

(2011) Hamed Rezaei et al.   ANNALS OF THE RHEUMATIC DISEASES

American College of Rheumatology/European League Against Rheumatism provisional definition of remission in rheumatoid arthritis for clinical trials

(2011) David T. Felson et al.   ARTHRITIS AND RHEUMATISM

Infections in patients treated with tumor necrosis factor antagonists: incidence, etiology and mortality in the BIOBADASER registry

(2011) María José Pérez-Sola et al.   MEDICINA CLINICA

Current evidence for a strategic approach to the management of rheumatoid arthritis with disease-modifying antirheumatic drugs: a systematic literature review informing the EULAR recommendations for the management of rheumatoid arthritis

(2010) R. Knevel et al.   ANNALS OF THE RHEUMATIC DISEASES

Evidence for treating rheumatoid arthritis to target: results of a systematic literature search

(2010) M. Schoels et al.   ANNALS OF THE RHEUMATIC DISEASES

EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs

(2010) J. S. Smolen et al.   ANNALS OF THE RHEUMATIC DISEASES

Treating rheumatoid arthritis to target: recommendations of an international task force

(2010) J. S. Smolen et al.   ANNALS OF THE RHEUMATIC DISEASES

Current evidence for the management of rheumatoid arthritis with biological disease-modifying antirheumatic drugs: a systematic literature review informing the EULAR recommendations for the management of RA

(2010) J. L. Nam et al.   ANNALS OF THE RHEUMATIC DISEASES

Drug-specific risk of tuberculosis in patients with rheumatoid arthritis treated with anti-TNF therapy: results from the British Society for Rheumatology Biologics Register (BSRBR)

(2009) W. G. Dixon et al.   ANNALS OF THE RHEUMATIC DISEASES

Addition of infliximab compared with addition of sulfasalazine and hydroxychloroquine to methotrexate in patients with early rheumatoid arthritis (Swefot trial): 1-year results of a randomised trial

(2009) RF van Vollenhoven et al.   LANCET

An explanation for the apparent dissociation between clinical remission and continued structural deterioration in rheumatoid arthritis

(2008) A. K. Brown et al.   ARTHRITIS AND RHEUMATISM

Comparison of methotrexate monotherapy with a combination of methotrexate and etanercept in active, early, moderate to severe rheumatoid arthritis (COMET): a randomised, double-blind, parallel treatment trial

(2008) Paul Emery et al.   LANCET